National Institutes of Health

Description

The purpose of this limited competition Funding Opportunity Announcement (FOA) is to continue the program of the National Cancer Institute (NCI) for the development of new anticancer therapies for adult patients with brain tumors, especially glioblastoma multiforme (GBM). This limited competition FOA solicits a single application from the current awardee of the Adult Brain Tumor Consortium (ABTC). The ABTC is a NCI-funded clinical trials group that performs clinical research on the treatment of patients with GBM. In this funding period, the ABTC is expected to remain focused on the early stage development of new agents for treatment of GBM. However, in addition to identifying agents with antitumor activity in patients participating in Phase I and II clinical trials, the Consortium will be expected to expand and enrich its translational research. These aspects include increased emphasis on the identification of the effects of anticancer agents on their intended targets and other studies to increase understanding of biological and molecular factors that may improve the response of GBM to new agents. ABTC must be capable of conducting comprehensive pharmacokinetic and pharmacodynamic evaluations, characterization of drug effects on relevant cellular targets (using appropriate biospecimens) and integrating such findings.

Who can apply

• Others

Contact

NIH OER Webmaster <br/>FBOWebmaster@OD.NIH.GOV <br/>
FBOWebmaster@OD.NIH.GOV